Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Risk of treatment-related esophageal cancer among breast cancer survivors.
Authors: Morton LM,  Gilbert ES,  Hall P,  Andersson M,  Joensuu H,  Vaalavirta L,  Dores GM,  Stovall M,  Holowaty EJ,  Lynch CF,  Curtis RE,  Smith SA,  Kleinerman RA,  Kaijser M,  Storm HH,  Pukkala E,  Weathers RE,  Linet MS,  Rajaraman P,  Fraumeni JF Jr,  Brown LM,  van Leeuwen FE,  Fossa SD,  Johannesen TB,  Langmark F,  Lamart S,  Travis LB,  Aleman BM
Journal: Ann Oncol
Date: 2012 Dec
Branches: OD, REB
PubMed ID: 22745217
PMC ID: PMC3501231
Abstract: BACKGROUND: Radiotherapy for breast cancer may expose the esophagus to ionizing radiation, but no study has evaluated esophageal cancer risk after breast cancer associated with radiation dose or systemic therapy use. DESIGN: Nested case-control study of esophageal cancer among 289 748 ≥5-year survivors of female breast cancer from five population-based cancer registries (252 cases, 488 individually matched controls), with individualized radiation dosimetry and information abstracted from medical records. RESULTS: The largest contributors to esophageal radiation exposure were supraclavicular and internal mammary chain treatments. Esophageal cancer risk increased with increasing radiation dose to the esophageal tumor location (P(trend )< 0.001), with doses of ≥35 Gy associated with an odds ratio (OR) of 8.3 [95% confidence interval (CI) 2.7-28]. Patients with hormonal therapy ≤5 years preceding esophageal cancer diagnosis had lower risk (OR = 0.4, 95% CI 0.2-0.8). Based on few cases, alkylating agent chemotherapy did not appear to affect risk. Our data were consistent with a multiplicative effect of radiation and other esophageal cancer risk factors (e.g. smoking). CONCLUSIONS: Esophageal cancer is a radiation dose-related complication of radiotherapy for breast cancer, but absolute risk is low. At higher esophageal doses, the risk warrants consideration in radiotherapy risk assessment and long-term follow-up.